v3.26.1
Nature of business and future operations (Details) - USD ($)
3 Months Ended
Jul. 21, 2026
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash   $ 92,600,000
Long-term debt   $ 0
Genevant Sciences Corporation    
Gain Contingencies [Line Items]    
Ownership interest in equity method investment (as a percentage)   16.00%
Moderna | Revenue from collaborations and licenses | Genevant    
Gain Contingencies [Line Items]    
Noncontingent settlement amount   $ 950,000,000.0
Additional noncontingent settlement amount pending   $ 1,300,000,000
Genevant | Subsequent Event    
Gain Contingencies [Line Items]    
Revenue recognized as portion of Settlement Agreement $ 1,000,000.0